BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 6, 2021
Product Development

Genmab’s strategy for going commercial

Genmab is preparing to join the expanding ranks of biotechs taking on commercialization, and CEO Jan van de Winkel is approaching commercial strategy with the same innovative eye he’s applied to development. ...
BioCentury | Sep 15, 2020

$21B deal by Gilead, none by PhRMA: a BioCentury podcast

After nearly 40 years as an independent company, $1.5 billion raised and a scuttled deal with Seattle Genetics, Immunomedics has been acquired by Gilead for $21 billion. What must the big biotech do to derive...
BioCentury | May 29, 2020

Taiho’s new modality search engine

With its parent company focused on small molecules for cancer, Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho Pharmaceutical beyond its internal expertise. President Sakae Asanuma established...
BioCentury | Feb 18, 2020

Canada’s Sagard gaining healthcare foothold via royalty fund

Canadian alternative asset management firm Sagard Holdings is dipping its toe into life sciences investments via a new royalty fund, which has raised $475 million in a first close. The firm isn’t disclosing the final...
BioCentury | Feb 7, 2020
Product Development

Roche, PTC provide first look at pivotal SMA data in adults

Roche and PTC reported the first pivotal data for a spinal muscular atrophy therapy in adults with established disease on Thursday when they unveiled the detailed data supporting their bid for risdiplam to treat SMA...
BioCentury | Jan 4, 2020

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BioCentury | Dec 4, 2019
Company News

Audentes takeout signals pharma's continued interest in gene therapy manufacturing

Gene therapy companies with their own manufacturing operations are continuing to catch the eye of big pharmas. In the wake of Astellas' $3 billion takeout of Audentes on Monday, several gene therapy players saw stock...
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
BioCentury | Jun 20, 2018

Channel your outrage

Before the dust settles on the PABNAB debacle, save some outrage for what really matters: not the periodic stripper party that screams “sickening,” but the entrenched attitudes and daily affronts that end up keeping women...
Items per page:
1 - 10 of 77